申请人:Japan Energy Corporation
公开号:US06399568B1
公开(公告)日:2002-06-04
A cyclic tetrapeptide derivative represented by the general formula (I):
wherein:
R11, R12, R21 and R22 independently denote a monovalent group selected from hydrogen, a linear or branched alkyl group with 6 or less carbon atoms, benzyl group, 4-methoxybenzyl group, 3-indolylmethyl group, (N-methoxy-3-indolyl) methyl group, (N-formyl-3-indolyl)methyl group, etc.; R3 denotes a divalent group selected from a linear chained hydrocarbon group with 3 or 4 carbon atoms, or the linear branched hydrocarbon group having a branched chain added to the chain, or a divalent group substituted with a heteroatom;
R4 denotes a divalent chained hydrocarbon group with 4 to 6 carbon atoms, or a divalent group derived from said hydrocarbon group by addition etc. of a branched chain on said chain; and a pharmaceutically acceptable salt thereof, or an analogous cyclic tetrapeptide derivative compound; as well as a histone deacetylase enzyme inhibitor, an MHC class-I molecule expression promoting agent and a pharmaceutical composition that comprise said cyclic tetrapeptide derivative as an effective ingredient.
一种由通式(I)表示的环状四肽衍生物:其中:R11、R12、R21和R22独立地表示从氢、6个或更少碳原子的线性或支链烷基、苯甲基、4-甲氧基苯甲基、3-吲哚甲基、(N-甲氧基-3-吲哚基)甲基、(N-甲酰基-3-吲哚基)甲基等中选择的单价基团;R3表示从具有3或4个碳原子的线性链烃基、或者添加了分支链到链上的线性支链烃基、或者被杂原子取代的二价基团中选择的二价基团;R4表示具有4到6个碳原子的二价链烃基,或者由在该链上添加了分支链等的该烃基衍生的二价基团;以及其药学上可接受的盐或类似的环状四肽衍生物化合物;以及作为有效成分的组成该环状四肽衍生物的组织脱乙酰化酶抑制剂、MHC-I类分子表达促进剂和药物组合物。